Randomization and stopped may BMS-354825 Src inhibitor need during the 12-month study constant. There were patients of F Is significantly more cant with severe bleeding in the clopidogrel group than in the placebo group. The clinical benefit of dual antiplatelet therapy pets over aspirin alone configuration was RMED in 207 patients undergoing PCI and in those with acute myocardial infarction with ST-segment elevation within 12 hours of 204-206 for 24 h after the onset of symptoms mine. In COMMIT, 204 the addition of clopidogrel to aspirin reduces mortality T and severe vascular Re events in h Capital 9%, corresponding to nine fewer events per 1000 patients treated for myocardial two weeks. Overall, if all transfused, t Dliche bleeding or stroke were considered, there was no significant additionally USEFUL risk of slope with the use of clopidogrel may need during the time of treatment are related, it was not about mass of major bleeding complications Older patients. 70 years or, where fi brinolytic therapy prior to randomization. Clopidogrel 204 was associated, however, dealt with a small but significant excess of minor bleeding slope of 4.7 per 1,000 patients. Under gr Sserer and minor bleeding as well, there was no obvious trend in terms of age in the excess risk of bleeding. 204 factors, the confinement to the remarkable safety of dual antiplatelet therapy in the COMMIT study Contributed Lich lack of a dose of clopidogrel, consistent use of low-dose aspirin, and the short duration of treatment k Nnten. Evidence of a more rapid onset of action and a gr Ere antiplatelet therapy with the use of a 600 mg rain t as a loading dose of 300 mg clopidogrel and 185 growing concern about the M Possibility, a significant proportion of patients achieve a suboptimal inhibition of platelet function with conventional doses of clopidogrel caused the CURRENT OASIS 7 trial. This study, accompanied by two two-factorial, of 25.086 patients with ACS, which was referred to a strategy of invasive treatment, such patients were randomized to either clopidogrel or clopidogrel double dose of standard-dose and low dose aspirin either h Here or lower dose of aspirin. The results of the comparison-dose aspirin were more studied tt. In the comparison of doses of clopidogrel, the rate of the first embodiment of the MI as death, stroke or vascular Ren in patients receiving a double dose versus standard-dose clopidogrel but 17.263 patients, the reduced undergoing PCI Similar double dose of clopidogrel Stent thrombosis in the co t an increase of major bleeding. 209 These results suggest that there is a T receiver singer of faster inhibition of platelet aggregation and completely Ndiger with a double dose of clopidogrel may need during the acute phase in patients with ACS. Contrary to fi nd a favorable environment supports the benefit of the t / benefit risk antiplatelet therapy in patients with ACS, 204206208 The same strategy was not good results when compared to aspirin alone given stable patients at high risk for atherothrombotic events Rocuronium 119302-91-9 with 203 or clopidogrel monotherapy in patients after isch ischemic stroke or TIA. 205 Although there are mechanistic reasons for this apparent heterogeneity t to be in treatment effect, it is important to note that the size E of additional keeping hereBenefit with dual antiplatelet therapy with aspirin alone in patients compared with ACS is only.